<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">77444</article-id><article-id pub-id-type="doi">10.7554/eLife.77444</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-268544"><name><surname>Kastenhuber</surname><given-names>Edward R</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1872-212X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-269427"><name><surname>Mercadante</surname><given-names>Marisa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-246709"><name><surname>Nilsson-Payant</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-269426"><name><surname>Johnson</surname><given-names>Jared L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-263402"><name><surname>Jaimes</surname><given-names>Javier A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6706-092X</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79944"><name><surname>Muecksch</surname><given-names>Frauke</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0132-5101</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200353"><name><surname>Weisblum</surname><given-names>Yiska</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9249-1745</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-269428"><name><surname>Bram</surname><given-names>Yaron</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-190220"><name><surname>Whittaker</surname><given-names>Gary R</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-265120"><name><surname>tenOever</surname><given-names>Benjamin R</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-268548"><name><surname>Schwartz</surname><given-names>Robert E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5417-5995</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-272679"><name><surname>Chandar</surname><given-names>Vasuretha</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-134226"><name><surname>Cantley</surname><given-names>Lewis</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1298-7653</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><institution content-type="dept">Department of Medicine</institution>, <institution>Weill Cornell Medical College</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Institute of Experimental Virology</institution>, <institution>TWINCORE Zentrum für Experimentelle und Klinische Infektionsforschung GmbH</institution>, <addr-line><named-content content-type="city">Hannover</named-content></addr-line>, <country>Germany</country></aff><aff id="aff3"><institution content-type="dept">Department of Microbiology and Immunology</institution>, <institution>Cornell University</institution>, <addr-line><named-content content-type="city">Ithaca</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Laboratory of Retrovirology</institution>, <institution>The Rockefeller University</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Department of Medicine</institution>, <institution>Weill Cornell Medicine</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Department of Microbiology</institution>, <institution>New York University Langone Medical Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-41027"><name><surname>van der Meer</surname><given-names>Jos W</given-names></name><role>Reviewing editor</role><aff><institution>Radboud University Medical Centre</institution>, <country>Netherlands</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>lcantley@med.cornell.edu</email> (LC);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>16</day><month>03</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e77444</elocation-id><history><date date-type="received"><day>08</day><month>02</month><year>2022</year></date><date date-type="accepted"><day>22</day><month>02</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Kastenhuber et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Kastenhuber et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-77444-v1.pdf"/><abstract><p>Coagulopathy is a significant aspect of morbidity in COVID-19 patients. The clotting cascade is propagated by a series of proteases, including factor Xa and thrombin. While certain host proteases, including TMPRSS2 and furin, are known to be important for cleavage activation of SARS-CoV-2 spike to promote viral entry in the respiratory tract, other proteases may also contribute. Using biochemical and cell-based assays, we demonstrate that factor Xa and thrombin can also directly cleave SARS-CoV-2 spike, enhancing infection at the stage of viral entry. Coagulation factors increased SARS-CoV-2 infection in human lung organoids. A drug-repurposing screen identified a subset of protease inhibitors that promiscuously inhibited spike cleavage by both transmembrane serine proteases as well as coagulation factors. The mechanism of the protease inhibitors nafamostat and camostat may extend beyond inhibition of TMPRSS2 to coagulation-induced spike cleavage. Anticoagulation is critical in the management of COVID-19, and early intervention could provide collateral benefit by suppressing SARS-CoV-2 viral entry. We propose a model of positive feedback whereby infection-induced hypercoagulation exacerbates SARS-CoV-2 infectivity.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AI35270</award-id><principal-award-recipient><name><surname>Whittaker</surname><given-names>Gary R</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R35CA197588</award-id><principal-award-recipient><name><surname>Cantley</surname><given-names>Lewis</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010304</institution-id><institution>Pershing Square Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Cantley</surname><given-names>Lewis</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Robert E Schwartz, is on the scientific advisory board for Miromatrix Inc and is a consultant and speaker for Alnylam Inc..</p></fn><fn fn-type="conflict" id="conf3"><p>Lewis Cantley, is a founder and member of the SAB of Agios Pharmaceuticals and a founder and former member of the SAB of Ravenna Pharmaceuticals (previously Petra Pharmaceuticals). These companies are developing novel therapies for cancer. Holds equity in Agios. Lewis Cantley's laboratory also received some financial support from Ravenna Pharmaceuticals..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All new plasmids will be made available through Addgene.</p></sec><supplementary-material><ext-link xlink:href="elife-77444-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>